获得性再生障碍性贫血克隆性进展为骨髓增生异常综合征/急性髓系白血病：19例临床分析及文献复习

OBJECTIVE: To analyze the clinical features of clonal evolution of acquired aplastic anemia (AA) into myelodysplastic syndrome/acute myeloid leukemia (AML) and review of literatures. METHODS: AA developing MDS/AML patients between December 1994 and December 2011 enrolled into this study to analyze t...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2015
Materias:
论著
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342519/
https://www.ncbi.nlm.nih.gov/pubmed/25854465
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.03.009
Descripción
Sumario:OBJECTIVE: To analyze the clinical features of clonal evolution of acquired aplastic anemia (AA) into myelodysplastic syndrome/acute myeloid leukemia (AML) and review of literatures. METHODS: AA developing MDS/AML patients between December 1994 and December 2011 enrolled into this study to analyze their clinical characteristics. RESULTS: During the median follow-up of 49(15–97) months, 19 patients evolved to MDS/AML, of whom 10, 8 and 1 were from VSAA, SAA and NSAA subgroups, respectively. The median G-CSF therapy was 270(29–510) days. There were monosomy 7 in 11(57.9%) of 19 patients with AA evolved to MDS/AML. The median AA evolved to MDS/AML was 33(11–88) months. The median MDS/AML transformation in responders(54.2 months) was significantly longer than of non-responders (25.7 months,P<0.01). CONCLUSION: AA patients could evolved into MDS/AML concomitant with abnormal karotype and worse prognosis.

Ejemplares similares